Equities researchers at Bank of America initiated coverage on shares of Legend Biotech (NYSE:BNR) in a note issued to investors on Monday, BenzingaRatingsTable reports. The firm set a “buy” rating and a $32.30 price target on the stock. Bank of America‘s price objective indicates a potential upside of 16.61% from the stock’s current price.
A number of other brokerages have also commented on BNR. Morgan Stanley assumed coverage on shares of Legend Biotech in a report on Tuesday, July 7th. They issued an “overweight” rating on the stock. Cowen assumed coverage on shares of Legend Biotech in a report on Tuesday, July 7th. They issued an “outperform” rating on the stock.
Shares of NYSE:BNR traded up $1.67 during trading on Monday, reaching $27.70. The company had a trading volume of 7,569 shares, compared to its average volume of 363,558. Legend Biotech has a 12 month low of $22.50 and a 12 month high of $32.40.
Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests.
Recommended Story: Trade War
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.